糖化白蛋白与CKD患者不良临床结局:前瞻性队列研究
该前瞻性队列研究纳入3110例非透析依赖性CKD患者,中位糖化白蛋白(GA)为18.7%,平均随访7.9年。GA最高四分位相比第二分位,ESKD、CVD和死亡的风险比分别为1.42、1.67和1.63。GA与CVD和死亡呈J型关联,且在合并糖尿病患者中,GA在HbA1c基础上增加预后价值。
要点
- GA水平与CKD患者ESKD、CVD和死亡风险独立相关,不受糖尿病状态影响。
- GA与CVD和死亡呈J型关联,最低GA水平也增加风险。
- 在合并糖尿病的CKD患者中,GA在HbA1c基础上提供额外预后信息。
核心结论
- 在CKD患者中,GA水平与ESKD、CVD和死亡风险独立相关,无论是否合并糖尿病。
- 在合并糖尿病的CKD患者中,GA在HbA1c基础上增加预后价值。
研究设计与样本
- 前瞻性队列研究,纳入慢性肾功能不全队列研究(CRIC)中3110例CKD患者。
- 暴露为基线GA水平,结局为 incident ESKD、CVD事件和全因死亡,采用Cox比例风险回归分析。
主要发现
- 平均年龄59.0±10.8岁,女性1357例(43.6%),糖尿病1550例(49.8%),GA中位数18.7%(IQR 15.8%-23.3%)。
- 平均随访7.9年,发生980例ESKD、968例CVD事件和1084例死亡。
- GA最高四分位相比第二分位(参照),ESKD、CVD和死亡的风险比分别为1.42(95% CI 1.19-1.69)、1.67(95% CI 1.39-2.01)和1.63(95% CI 1.37-1.94)。
- GA与CVD和死亡的关联呈J型,最低GA水平也见风险增加。
- 在合并糖尿病的CKD患者中,调整HbA1c后GA与结局的关联仍显著,且同时加入GA和HbA1c显著增加新预后信息比例。
临床怎么用
- GA可作为CKD患者血糖监测和风险分层的补充指标,尤其适用于合并糖尿病患者。
- 临床解读GA时需注意其与CVD和死亡的J型关联,过低GA水平也提示风险增加。
局限性
- 缺乏纵向GA测量。
- 非糖尿病患者中HbA1c测量大部分缺失。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
RATIONALE & OBJECTIVE: Hemoglobin A1c (HbA1c) is widely used to estimate glycemia, yet it is less reliable in patients with chronic kidney disease (CKD). There is growing interest in the complementary use of glycated albumin (GA) to improve glycemic monitoring and risk stratification. However, whether GA associates with clinical outcomes in a non-dialysis-dependent CKD population remains unknown. STUDY DESIGN: Prospective cohort study. SETTING & PARTICIPANTS: 3,110 participants with CKD from the Chronic Renal Insufficiency Cohort study. EXPOSURE: Baseline GA levels. OUTCOME: Incident end-stage kidney disease (ESKD), cardiovascular disease (CVD) events, and all-cause mortality. ANALYTICAL APPROACH: Cox proportional hazards regression. RESULTS: Participant characteristics included mean age 59.0±10.8 SD years; 1,357 (43.6%) female; and 1,550 (49.8%) with diabetes. The median GA was 18.7% (IQR, 15.8%-23.3%). During an average 7.9-year follow-up, there were 980 ESKD events, 968 CVD events, and 1,084 deaths. Higher GA levels were associated with greater risks of all outcomes, regardless of diabetes status: hazard ratios for ESKD, CVD, and death among participants with the highest quartile compared with quartile 2 (reference) were 1.42 (95% CI, 1.19-1.69), 1.67 (95% CI, 1.39-2.01), and 1.63 (95% CI, 1.37-1.94), respectively. The associations with CVD and death appeared J-shaped, with increased risk also seen at the lowest GA levels. Among patients with coexisting CKD and diabetes, the associations of GA with outcomes remained significant even after adjusting for HbA1c. For each outcome, we observed a significant increase in the fraction of new prognostic information when both GA and HbA1c were added to models. LIMITATIONS: Lack of longitudinal GA measurements; and HbA1c measurements were largely unavailable in participants without diabetes. CONCLUSIONS: Among patients with CKD, GA levels were independently associated with risks of ESKD, CVD, and mortality, regardless of diabetes status. GA added prognostic value to HbA1c among patients with coexisting CKD and diabetes. PLAIN-LANGUAGE SUMMARY: Hemoglobin A1c (HbA1c) is widely used to estimate glycemia, yet it is less reliable in patients with chronic kidney disease (CKD). There is growing interest in the complementary use of glycated albumin (GA) to improve glycemic monitoring and risk stratification. However, whether GA associates with clinical outcomes in a non-dialysis-dependent CKD population remains unknown. In this cohort study of 3,110 individuals with non-dialysis-dependent CKD, GA levels were independently associated with risks of end-stage kidney disease, cardiovascular disease (CVD), and mortality. The associations with CVD and mortality appeared to be J-shaped. Among patients with coexisting CKD and diabetes, GA added prognostic value to HbA1c. Thus, GA may be a valuable complementary test to HbA1c in patients with CKD.
引用
- Tang M, Berg AH, Zheng H, et al. Glycated Albumin and Adverse Clinical Outcomes in Patients With CKD: A Prospective Cohort Study. Am J Kidney Dis. 2024. PMID: 38518919. doi:10.1053/j.ajkd.2024.02.006
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。